US anti-virals major Gilead Sciences’ (Nasdaq: GILD) Kite unit and Arcellx Nasdaq: ACLX) announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program.
The collaboration was started in 2020 and expanded in November last year. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’ novel and compact D-Domain binder.
The companies shared the design of a global, Phase III randomized controlled clinical trial, iMMagine-3, which Kite expects to start in the second half of this year. The trial will compare the efficacy and safety of anito-cel randomized against the standard of care (SOC) in patients with relapsed and/or refractory multiple myeloma (rrMM) who have received one to three prior lines of therapy, including an immunomodulatory drug (lMiD) and an anti-CD38 monoclonal antibody.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze